TuisHELP • NASDAQ
add
Cybin Inc
Vorige sluiting
$7,61
Dagwisseling
$7,22 - $8,10
Jaarwisseling
$5,76 - $8,97
Gemiddelde volume
520,82 k
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CAD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 33,24 m | 31,95% |
Netto inkomste | -30,58 m | -43,25% |
Netto winsgrens | — | — |
Wins per aandeel | -1,46 | -92,11% |
EBITDA | -33,19 m | -32,03% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CAD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 135,02 m | -35,39% |
Totale bates | 258,62 m | -14,37% |
Totale aanspreeklikheid | 21,42 m | 112,14% |
Totale ekwiteit | 237,20 m | — |
Uitstaande aandele | 23,03 m | — |
Prys om te bespreek | 0,69 | — |
Opbrengs op bates | -32,45% | — |
Opbrengs op kapitaal | -34,81% | — |
Kontantvloei
Netto kontantverandering
| (CAD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -30,58 m | -43,25% |
Kontant van bedrywe | -21,11 m | -1,96% |
Kontant van beleggings | -1,08 m | -404,19% |
Kontant van finansiering | 20,98 m | -89,01% |
Netto kontantverandering | -1,27 m | -100,75% |
Beskikbare kontantvloei | -11,14 m | 12,30% |
Meer oor
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Gestig
2019
Hoofkwartier
Webwerf
Werknemers
50
